GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Notes Receivable

ADC Therapeutics (ADC Therapeutics) Notes Receivable : $0.00 Mil (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Notes Receivable?

ADC Therapeutics's Notes Receivable for the quarter that ended in Dec. 2023 was $0.00 Mil.


ADC Therapeutics Notes Receivable Historical Data

The historical data trend for ADC Therapeutics's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Notes Receivable Chart

ADC Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Notes Receivable
Get a 7-Day Free Trial - - - - -

ADC Therapeutics Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

ADC Therapeutics Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


ADC Therapeutics Notes Receivable Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


ADC Therapeutics (ADC Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.